Au­rinia fails to find buy­er, will shed pipeline to fo­cus on Lup­ky­nis

Au­rinia Phar­ma­ceu­ti­cals said it was un­able to at­tract any for­mal of­fers dur­ing its strate­gic re­view process, which be­gan last sum­mer af­ter calls from share­hold­ers MKT Cap­i­tal and Iljin SNT for changes at the US-Cana­di­an drug­mak­er.

Af­ter reach­ing out to more than 60 par­ties, on­ly one gave a non-bind­ing ex­pres­sion of in­ter­est, but ze­ro for­mal of­fers came through, Au­rinia said Thurs­day morn­ing. The biotech, which mar­kets one drug, said it al­so didn’t find any wor­thy com­pa­nies or as­sets to bring in­to its own fold.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER